MA29694B1 - Derives de l'imidazopyridine comme ligands du recepteur cannabinoide - Google Patents

Derives de l'imidazopyridine comme ligands du recepteur cannabinoide

Info

Publication number
MA29694B1
MA29694B1 MA30633A MA30633A MA29694B1 MA 29694 B1 MA29694 B1 MA 29694B1 MA 30633 A MA30633 A MA 30633A MA 30633 A MA30633 A MA 30633A MA 29694 B1 MA29694 B1 MA 29694B1
Authority
MA
Morocco
Prior art keywords
cannabinoid receptor
ligands
imidazopyridine derivatives
diseases
derivatives
Prior art date
Application number
MA30633A
Other languages
English (en)
Inventor
Andrew John Eatherton
Gerard Martin Paul Giblin
William Leonard Mitchell
Alan Naylor
Lee William Page
Martin Swarbrick
Jennifer Anne Sweeting
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0516380A external-priority patent/GB0516380D0/en
Priority claimed from GB0524324A external-priority patent/GB0524324D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA29694B1 publication Critical patent/MA29694B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Dérivés d'imidazopyridine servant de ligands des récepteurs de cannabinoïdes La présente invention concerne des dérivés d'imidazopyridine nouveaux, des compositions pharmaceutiques contenant ces composés et leur utilisation dans le traitement de maladies, en particulier de la douleur, maladies qui sont provoquées directement ou indirectement par une augmentation ou diminution d'activité du récepteur de cannabinoïdes.
MA30633A 2005-08-09 2008-02-08 Derives de l'imidazopyridine comme ligands du recepteur cannabinoide MA29694B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0516380A GB0516380D0 (en) 2005-08-09 2005-08-09 Compounds
GB0524324A GB0524324D0 (en) 2005-11-29 2005-11-29 Compounds

Publications (1)

Publication Number Publication Date
MA29694B1 true MA29694B1 (fr) 2008-08-01

Family

ID=37192394

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30633A MA29694B1 (fr) 2005-08-09 2008-02-08 Derives de l'imidazopyridine comme ligands du recepteur cannabinoide

Country Status (17)

Country Link
US (1) US20080221097A1 (fr)
EP (1) EP1912985A1 (fr)
JP (1) JP2009504587A (fr)
KR (1) KR20080034457A (fr)
AR (1) AR055601A1 (fr)
AU (1) AU2006278191A1 (fr)
BR (1) BRPI0614272A2 (fr)
CA (1) CA2618165A1 (fr)
CR (1) CR9787A (fr)
EA (1) EA200800562A1 (fr)
IL (1) IL188924A0 (fr)
MA (1) MA29694B1 (fr)
MX (1) MX2008001935A (fr)
NO (1) NO20081195L (fr)
PE (1) PE20070239A1 (fr)
TW (1) TW200734335A (fr)
WO (1) WO2007017237A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0705803D0 (en) * 2007-03-28 2007-05-02 Glaxo Group Ltd Novel compounds
AU2010231694A1 (en) 2009-03-30 2011-10-06 Astellas Pharma Inc. Pyrimidine compound
EP2534137B1 (fr) 2010-02-08 2015-09-16 Allergan, Inc. Dérivés de pyridazine en tant qu' agonistes du cannabinoïde-2
SI2599774T1 (sl) * 2010-07-29 2017-03-31 Astellas Pharma Inc. Zgoščene piridinske spojine kot CB2 kanabinoidni receptorski ligandi

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0113245B1 (fr) * 1982-12-29 1989-03-15 Kureha Kagaku Kogyo Kabushiki Kaisha Dérivés de céphalosporine
US5112820A (en) * 1990-03-05 1992-05-12 Sterling Drug Inc. Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US6696448B2 (en) * 1996-06-05 2004-02-24 Sugen, Inc. 3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
ATE237023T1 (de) * 1998-01-23 2003-04-15 Voith Paper Patent Gmbh Verfahren zur entfernung von feinen verunreinigungen aus einer faserstoffsuspension
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US7332494B2 (en) * 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
WO2002020002A2 (fr) * 2000-09-06 2002-03-14 Ortho Mcneil Pharmaceutical, Inc. Methode de traitement des allergies
US20040063744A1 (en) * 2002-05-28 2004-04-01 Tao Wang Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
ATE340785T1 (de) * 2002-08-21 2006-10-15 Glaxo Group Ltd 2-phenylamino-4-trifluoromethyl-5-(benzyl- oder pyridin-4-ylmethyl)carbamoylpyrimidin-derivate als selektive cb2 cannabinoid-rezeptor modulatoren
GB0222493D0 (en) * 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
AU2004213375A1 (en) * 2003-02-14 2004-09-02 Wyeth Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-Hydroxytryptamine-6 ligands
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
UY28945A1 (es) * 2004-06-09 2006-01-31 Glaxo Group Ltd Derivados de pirrolopiridina

Also Published As

Publication number Publication date
EP1912985A1 (fr) 2008-04-23
PE20070239A1 (es) 2007-04-01
AU2006278191A1 (en) 2007-02-15
BRPI0614272A2 (pt) 2011-03-22
AR055601A1 (es) 2007-08-29
TW200734335A (en) 2007-09-16
EA200800562A1 (ru) 2008-06-30
US20080221097A1 (en) 2008-09-11
NO20081195L (no) 2008-04-28
CA2618165A1 (fr) 2007-02-15
JP2009504587A (ja) 2009-02-05
WO2007017237A1 (fr) 2007-02-15
CR9787A (es) 2008-05-05
IL188924A0 (en) 2008-08-07
MX2008001935A (es) 2008-03-26
KR20080034457A (ko) 2008-04-21

Similar Documents

Publication Publication Date Title
MA27448A1 (fr) Derives de pyridine modulateurs du recepteur cb2
MA27428A1 (fr) Derives de pyrimidine et leur utilisation en tant que modulateurs cb2
TW200611695A (en) Pyrrolopyridine derivatives
DE60309739D1 (de) Pyridinderivate als modulatoren des cb2-rezeptors
MA30077B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
MA28680B1 (fr) 3-aminocyclopentanecarboxamides utiles comme modulateurs de récepteurs de chimiokines
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
MA28681B1 (fr) 3-aminocyclopentanecarboxamides utiles comme modulateurs de récepteurs de chimiokines
MA34650B1 (fr) Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane
DK1651615T3 (da) Pyridazinyl-piperaziner og anvendelse deraf som histamin-H3-receptorligander
EA200601798A1 (ru) Замещенные соединения морфолина для лечения расстройств центральной нервной системы
AP1503A (en) Benzimidazole and pyridylimidazole derivatives as ligands for GABA receptors
MA29693B1 (fr) Derives de xanthine en tant qu'agonistes hm74a selectifs
MA27675A1 (fr) Derives de piperazine et leur utilisation dans le traitement de maladies neurologiques et psychiatriques
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
DE602004013563D1 (de) Rantagonisten
EA200501504A1 (ru) Лиганды каннабиноидных рецепторов и их применение
MA30778B1 (fr) Derives de sulfonamides servant d'agonistes adrenergique et d'antagonistes muscariniques
NO20064238L (no) Imidazolinderivater med CB1 agonistlsk aktivitet
MA30410B1 (fr) Dimeres de derives d'artemisinine, leur preparation et leur application en therapeutique.
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA32282B1 (fr) Dérivés de 2-phényl-pyridine substitués
DE60004654D1 (de) 4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden
DE602004011204D1 (de) Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.